Medicis receives two patents for Loprox gel

By Elaine Rigoli

Tampa, Fla., April 12 - Medicis announced that the U.S. Patent and Trademark Office has issued two patents relating to Loprox gel (0.77% ciclopirox).

U.S. Patent No. 7,018,656 covers the Loprox gel composition, while U.S. Patent No. 7,026,337 covers the use of Loprox gel in the treatment of skin infections such as athlete's foot and ringworm.

Both of these newly issued patents are exclusively licensed to Medicis and expire in 2018, according to a company news release.

Patent applications are pending for other forms of Loprox.

Located in Scottsdale, Ariz., Medicis is a specialty pharmaceutical company focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.